companiesCompany

Advanced Accelerator Applications (Novartis)

The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.

AAA developed Lutathera (177Lu-DOTATATE) and the Netspot 68Ga-DOTATATE kit before its $3.9 billion acquisition by Novartis in 2018; as Novartis' radioligand unit it manufactures Locametz (68Ga-PSMA-11 kit) and Pluvicto and runs the Novartis radioligand production network in Europe and the US.

Headquarters

Saint-Genis-Pouilly, FR

Scorecard

All companies

#46of 680 companies, score 48

approved products +18
targets +4
modalities +4
regions +5
24-month regulatory events +4
registry trials +13

3 approved, 0 in phase 3, 0 earlier, 2 targets, 40 registry studies. Formula on the scorecards page.

Type

radiopharma

Website

www.adacap.com

Founded

2002

Products

3top

ApprovedPET imaging agent kit (PSMA, gallium-68)

Locametz (kit for Ga-68 gozetotide) · Locametz

Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.

ApprovedPET radiotracer (somatostatin receptor ligand)

Gallium-68 DOTATATE (and Cu-64 DOTATATE) · Netspot / Detectnet

The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).

ApprovedRadioligand therapy (beta)

Lutetium-177 vipivotide tetraxetan · Pluvicto

A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.